EL7.AI
StocksMediumUpdated×3•Originally published 24 September 2026•Updated 24 September 2026•
2 min read

Satellos Gets FDA Clearance for Forazapadin in FSHD, Funding of Up to $5 Million

Key Facts

1The FDA cleared the forazapadin IND for FSHD; Satellos targets a Phase 2 start in the fourth quarter (Q4) of 2026.
2FSHD Canada Foundation agreed to conditional funding of up to US$5 million for a capped share of future FSHD proceeds.
3The proposed placebo-controlled Phase 2 study tests 60 mg and 120 mg in adults aged 18 or older.

In a move that bolsters investor confidence in the biotech sector, Satellos Bioscience announced that the U.S. FDA cleared its IND application to study forazapadin in patients with FSHD. The company aims to launch a Phase 2 study in Q4 2026, supported by a $5 million funding agreement with the FSHD Canada Foundation. According to reports, the market reacted positively to this clearance, which transitions the program from regulatory preparation to active clinical testing.

Regarding the financial context, this non-dilutive funding supplements the company's cash position, which stood at $61.8 million in June 2026 compared to $27.7 million at year-end 2025. Per market data, MSLE shares rose following the announcement, moving upward from the September 23 close of $8.41. The funding is structured as milestone-based payments over the next five quarters, potentially reducing the immediate need for dilutive equity financing for this specific program.

Investors should watch MSLE shares, which are trading above the $8.41 level (close of September 23, 2026), as the company prepares to initiate the study in Q4 2026. The upcoming calendar features additional catalysts for the company in late 2026, including data releases from the BASECAMP trial and updates on the TRAILHEAD study. The successful execution of these milestones will be critical in validating the clinical hypothesis for forazapadin and its impact on market valuation.

Open on chart